ABBV AbbVie Inc

  1. Stocks
  2. Healthcare
  3. NYSE: ABBV

Price (delayed)

$135.21

Market cap

$239.04B

P/E Ratio

32.58

Dividend/share

$5.31

EPS

$4.15

Enterprise value

$307.57B

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate ...

Highlights
ABBV's revenue is up by 36% year-on-year and by 2.7% since the previous quarter
ABBV's gross profit is up by 34% year-on-year and by 6% since the previous quarter
ABBV's P/E is 34% above its 5-year quarterly average of 24.3 but 3.3% below its last 4 quarters average of 33.7
The EPS has grown by 13% from the previous quarter but it has contracted by 13% YoY
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: https://www.abbvie.com/
Peers: PFE BMY LLY AMGN

Key stats

What are the main financial stats of ABBV
Market
Shares outstanding
1.77B
Market cap
$239.04B
Enterprise value
$307.57B
Valuations
Price to earnings (P/E)
32.58
Price to book (P/B)
17.63
Price to sales (P/S)
4.34
EV/EBIT
31.93
EV/EBITDA
16.86
EV/Sales
5.58
Earnings
Revenue
$55.17B
EBIT
$9.63B
EBITDA
$18.24B
Free cash flow
$21.68B
Per share
EPS
$4.15
Free cash flow per share
$12.25
Book value per share
$7.67
Revenue per share
$31.17
TBVPS
$22.09
Balance sheet
Total assets
$148.86B
Total liabilities
$135.28B
Debt
$80.72B
Equity
$13.55B
Working capital
$424M
Liquidity
Debt to equity
5.96
Current ratio
1.01
Quick ratio
0.75
Net debt/EBITDA
3.76
Margins
EBITDA margin
33.1%
Gross margin
67.7%
Net margin
13.7%
Operating margin
30.1%
Efficiency
Return on assets
5%
Return on equity
57%
Return on invested capital
11.9%
Return on capital employed
8%
Return on sales
17.5%
Dividend
Dividend yield
3.93%
DPS
$5.31
Payout ratio
128%

ABBV stock price

How has the AbbVie stock price performed over time
Intraday
-1.15%
1 week
-1.52%
1 month
4.39%
1 year
20.53%
YTD
-0.14%
QTD
-0.14%

Financial performance

How have AbbVie's revenue and profit performed over time
Revenue
$55.17B
Gross profit
$37.36B
Operating income
$16.6B
Net income
$7.53B
Gross margin
67.7%
Net margin
13.7%
The operating income has grown by 44% YoY and by 7% from the previous quarter
ABBV's revenue is up by 36% year-on-year and by 2.7% since the previous quarter
ABBV's gross profit is up by 34% year-on-year and by 6% since the previous quarter
The net margin has declined by 25% year-on-year but it rose by 10% since the previous quarter

Growth

What is AbbVie's growth rate over time

Valuation

What is AbbVie stock price valuation
P/E
32.58
P/B
17.63
P/S
4.34
EV/EBIT
31.93
EV/EBITDA
16.86
EV/Sales
5.58
ABBV's P/E is 34% above its 5-year quarterly average of 24.3 but 3.3% below its last 4 quarters average of 33.7
The EPS has grown by 13% from the previous quarter but it has contracted by 13% YoY
ABBV's price to book (P/B) is 21% higher than its last 4 quarters average of 14.6
AbbVie's equity has decreased by 11% YoY but it has increased by 8% from the previous quarter
ABBV's revenue is up by 36% year-on-year and by 2.7% since the previous quarter
ABBV's P/S is 17% above its last 4 quarters average of 3.7 and 6% above its 5-year quarterly average of 4.1

Efficiency

How efficient is AbbVie business performance
The ROE has plunged by 72% YoY but it has grown by 17% from the previous quarter
The ROS has contracted by 29% YoY but it has grown by 11% from the previous quarter
AbbVie's return on assets has decreased by 19% YoY but it has increased by 11% QoQ
AbbVie's ROIC has increased by 17% from the previous quarter but it has decreased by 9% YoY

Dividends

What is ABBV's dividend history
Dividend details
DPS
$5.31
Dividend yield
3.93%
Payout ratio
128%
Recent dividends

Financial health

How did AbbVie financials performed over time
AbbVie's total assets is 10% higher than its total liabilities
The quick ratio has grown by 15% from the previous quarter and by 10% YoY
ABBV's current ratio is up by 11% since the previous quarter and by 6% year-on-year
AbbVie's equity has decreased by 11% YoY but it has increased by 8% from the previous quarter
The company's debt to equity fell by 9% QoQ but it rose by 4.6% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.